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p-value < 0.001) ConClusions: BMI was negatively associated with HRQoL based 
on the multivariate regression analysis among Korean diabetic patients with HbA1c 
≥ 6.5, after adjusting for confounding factors. This finding alerts diabetic patients to 
the danger of the weight gain as it is related to the lower quality of life.
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introduCtion: Compared with multiple daily injections, insulin pump therapy 
(continuous subcutaneous insulin infusion - CSII) improves glucose control in 
patients with type 1 diabetes mellitus (T1DM). When CSII is combined with continu-
ous glucose monitoring (CGM) with automated low glucose insulin suspension (LGS), 
exposure to hypoglycaemia is significantly reduced. Patients with impaired hypogly-
caemia awareness (IHA) are at increased risk of severe hypoglycaemia, so the ben-
efits of this technology should be evident in patient reported health-related quality 
of life (HRQoL). objeCtives: To compare HRQoL in T1DM patients with IHA treated 
with CSII alone or CSII with CGM + LGS in this 6 month, prospective, single centre 
RCT. Methods: T1DM patients with IHA and CSII experience were randomised to 
either CSII alone (control, n= 49) or CSII with CGM + LGS (treatment, n= 46). Patients 
> 12 years were included in this analysis (n= 64, male 50%, age 23.2 ± 11.9 years, 
diabetes duration 13.8 ± 9.5 years, CSII duration 4.9 ± 3.6 years, Hypoglycaemia 
Awareness score 6.2 ± 1.4). Hypoglycaemia Fear survey (HFS) and HRQoL (EQ5D) 
were analysed using ANCOVA least-squares mean change from baseline to 6 months 
post-randomisation. results: Enrolled patients were not appreciably impaired at 
baseline (EQ5D Utility mean +SD 0.96+0.07), but overall gains in treatment group 
(+0.038) and decrements in control (-0.035) over 6 months produced a significant 
comparative utility gain for the intervention (LS mean difference 0.073, 95% CI: 
0.008-0.139, p= 0.028). Although not statistically significant, supporting trends were 
noted in EQ5D VAS and HFS (Worry subscale). ConClusions: Success of T1DM 
treatment relies upon effective and compliant self-management, so the patient 
perspective is relevant when evaluating treatment options and determining the 
impact on aspects of daily life. This analysis further supports the important role of 
insulin pump therapy plus CGM with automated LGS in the effective management 
of T1DM patients with IHA.
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objeCtives: To analyse the quality of life in insulin-dependent patients and 
resource consumption due to poor metabolic control after the standarization of 
glycated hemoglobin measure with A1CNOW+ and the glycemia measure with 
CONTOUR USB. Methods: An observational, prospective, multicentre study in 
patients with diabetes, insulin-dependent, with poor metabolic control has been 
conducted. Distribution of the ESDQOL questionnaire which contains the domains 
satisfaction, impact, social /vocational, concern regarding diabetes and degree of 
perception of QoL at baseline, at 3 and 6 months. The score of the domains and the 
full questionnaire is measured on a scale 0-100; where lower scores indicate a higher 
QoL. Also, Visual Analogic Scale was used to assess the patient’s own perception 
of their quality of life. The resource consumption is analysed for urgent attention 
due to poor metabolic control, the use of resources included are visits to emergency 
department, income, length of hospital stay and additional consultations. results: 
The evolution of the domains in satisfaction goes from 35.9 at baseline to 31.5 at 
6 months. The impact improves from 27.9 at baseline to 26.0 at 6 months, social/
vocational concern 25, 8 to 22.4 as well as concerns related to diabetes from 37.7 
to 33, 1. Also the degree of perceived improvement in VAS was 2.1 points. All ana-
lysed results were statistically significant. At baseline there were 26 patients (7.9%) 
who required urgent attention due to poor metabolic control in the previous 3 
months versus 9 patients (2.8) who requested urgent attention on data collected at 
6 months. ConClusions: CONTOUR USB device to measure glycemia and A1CNow 
device to measure HbA1C improve the quality of life of patients and reduce the use 
of resources due to poor control.
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objeCtives: Two surveys aimed to understand the impact of nocturnal and daytime 
non-severe hypoglycaemic events on health care system utilisation and patient 
quality of life. Methods: People with diabetes from six countries who had expe-
rienced a non-severe hypoglycaemic event in the 4 weeks prior to the survey were 
eligible (n= 300/survey). In South Africa, surveys were conducted online. results: 
In the South African nocturnal (N)/daytime (D) hypoglycaemia cohorts (n= 50/sur-
vey), 80% and 80% (N/D) had type 2 diabetes; 30%/24% (N/D) were male; mean age 
45/43 years (N/D); mean diabetes duration 11.1/9.4 years (N/D); 93/93% (N/D) insu-
lin users. 34/40% (N/D) experienced ≥ 1 non-severe hypoglycaemia events/week. 
Most respondents (70/76% [N/D]) were unemployed, which could skew the observed 
impact of hypoglycaemia on productivity. Both surveys revealed that, following 
an event, it took 20 min (median) for acute symptoms to disappear and 60 min 
(median) for the respondent to function at their normal level. After an event, 11/11% 
(N/D) decreased insulin dose, 14/12% (N/D) modified insulin administration time 
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objeCtives: CANA is a sodium glucose co-transporter 2 inhibitor developed for 
the treatment of T2DM. In a Phase 3 multi-national, randomised, double-blind, 
placebo- and active-controlled study, CANA improved glycaemia and reduced body 
weight and systolic blood pressure compared with placebo and SITA in subjects 
with T2DM on background metformin. Herein we report post-hoc analyses of the 
HRQoL and WRQoL data. Methods: WRQoL and HRQoL were measured using the 
Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and the 36-item Short Form 
(SF-36) at baseline, Week 26, and Week 52; with both instruments, higher scores 
indicate better quality of life. Data were analysed for CANA 100 (n= 368) and 300 
mg (n= 367), and SITA 100 mg (n= 366). Least-squares mean changes were evaluated 
using ANCOVA models; gender, anti-hyperglycaemic adjustment, baseline score, 
and treatment as covariates. results: Improvements from baseline to Weeks 26 
and 52 were detected for WRQoL total, physical function, and self-esteem scores in 
the CANA (both doses) and SITA groups (95% CI excludes zero), and for the other 
WRQoL domains, there was either improvement or no difference. A comparison 
of CANA 300 mg versus SITA at Week 26 suggests a difference in physical function 
(p= 0.0374). Improvements from baseline to Weeks 26 and 52 were also detected 
for HRQoL general health scores in the CANA (both doses) and SITA groups (95% 
CI excludes zero), and for other domains, there was either improvement or no 
difference. Other HRQoL results suggest possible differences in bodily pain (Week 
26, CANA 100 mg vs. SITA, p= 0.0518) and the mental component summary score 
(Week 52, CANA 300 mg vs. SITA, p= 0.0908). ConClusions: CANA and SITA were 
associated with improvements in WRQoL and HRQoL over 1 year in dual therapy. 
Results suggest that CANA is associated with a greater positive impact on patients 
versus SITA.
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objeCtives: With the increasing use of patient reported outcome measures in 
diabetes, it is important to understand which dimensions are most relevant to 
clinical indicators, and are the most predictive when assessing clinical change over 
time. This is important as the PROM scores can help inform the development of 
tailored therapeutics by highlighting the psychosocial functioning and quality of life 
impacts of different treatments. The aim of this study is to assess the relationship 
between the Diabetes Health Profile (DHP-18) and diabetes specific clinical vari-
ables to investigate how the measure can be used in the assessment of the impacts 
of different related complications and treatments. Methods: The relationship 
between the DHP-18 and a number of variables, including diabetes specific and co-
morbid health complications and length of time diagnosed were assessed. This was 
done cross-sectionally and longitudinally using a large dataset of Type 1 and Type 
2 people with diabetes (n= 1,802) collected in one United Kingdom health authority 
area. The analysis was carried out using Ordinary Least Squares and Logit regres-
sion. results: The Psychological distress domain is significantly associated with 
eye and foot related complications, and a number of co-morbid conditions including 
depression. The Barriers to activity domain is significantly associated with eye and 
foot related complications, duration of diabetes and a range of co-morbid conditions. 
The Disinhibited eating domain is related to duration of diabetes and co morbid 
conditions such as bone and lung disease. The number of associated problems was 
also a key predictive variable. ConClusions: The findings indicate that there is 
relationship between psychosocial functioning as measured by the DHP-18 and a 
range of clinical indicators. Tailored therapeutics can be used to change or reduce 
clinical concerns while also impacting on a patient’s psychosocial functioning and 
quality of life, and the DHP can be used to efficiently measure this.
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objeCtives: Little is known about the impact of body mass index (BMI) on health-
related quality of life (HRQoL) for diabetics in the Korean population. The aim of 
this study was to estimate the association between BMI and HRQoL of type 2 dia-
betic patients in Korea. Methods: This study is a cross-sectional analysis of adults 
who participated in 4th (2007-2009) and 5th (2010-2011) Korean National Health and 
Nutritional Examination Survey(total, 42,347 participants). HRQoL was measured 
by EuroQoL five-dimension (EQ-5D) and its association with BMI was investigated 
in Korean diabetic patients, especially those who did not have adequate control of 
blood glucose (HbA1c ≥ 6.5). Multivariate linear regression was performed at p-value 
of 0.05 with the use of SAS software, version 9.2. results: Out of 42,347 partici-
pants, 9.04% had diagnosed of diabetes. Among 2,726 diabetic patients in Korea, 
we assessed the association in 1,838 patients (median age 63) whose diabetes was 
not adequately controlled. We found that BMI was significantly negative associated 
with HRQoL(-0.0038, p-value < 0.001), after adjusting for age, sex, education, income, 
marital status, smoking status, alcohol, HbA1c, insulin treatment status, oral anti-
diabetic drug therapy, history of hypertension/high cholesterol/high triglyceride 
prevalence, stress level, and depression for more than two weeks. EQ-5D index 
decreased with rising BMI in Korean diabetic patients with HbA1c ≥ 6.5(-0.0038, 
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objeCtives: Since 2008, the Caisse Nationale d’Assurance Maladie des Travailleurs 
Salariéshas set up a diabetic patient support programme in ten pilot depart-
ments in France. In addition to written advice, programme members also have 
access to telephone support from health education nurses. In 2010, the sophia 
programme was extended to another nine departments and, at the beginning of 
2013, it was generalized to all French departments. The present study evaluated 
the health economics impact of the programme after a follow-up of 3 years. This 
analysis follows a preliminary assessment that demonstrated positive results 
after 1 year. Methods: The variation of various health care use indicators as 
well as outpatient and inpatient costs was compared between three cohorts: 
members of pilot departments, non-members, and a control group of diabetic 
patients living in departments in which sophia was not available. Results are 
adjusted for between-group differences observed at the beginning of the pro-
gramme. results: Adjusted analysis showed that, after matching for all other 
characteristics, compliance with recommended examinations improved to a much 
greater extent among programme members than among control subjects and 
non-members. Although all health care costs continued to increase in each cohort, 
outpatient and inpatient expenditure was € 226 lower for programme members 
than for controls for the period 2009-2011: -€ 54 for outpatient care and -€ 172 
for inpatient care. Although the outpatient expenditure of programme members 
was higher (+€ 40) for outpatient visits and medical procedures, their paramedical 
expenditure was lower (-€ 89). Hospitalization rates for diabetes were significantly 
lower among members than among controls. ConClusions: These results con-
firm the significant impact of the sophia programme on compliance with clinical 
practice guidelines in diabetology, hospitalization rates, and the 3-year growth of 
outpatient and inpatient costs. An assessment of the impact of the sophia pro-
gramme on clinical parameters will be conducted in the near future.
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objeCtives: To evaluate the consistency of T2DM management by French GPs in 
2012 versus 2013 HAS guidelines that recommend modulating glycaemic objec-
tives depending on patient’s profile. To assess current treatment need for T2DM 
patients. Methods: A transversal study, based on the IMS LifeLinkTM prospective 
Diabetes Cohort linked to Electronic Medical Records database (Disease Analyzer) 
was used to investigate patients’ profiles (age, disease history and complications, 
renal impairment, cardiovascular events, co-morbidities), HbA1c, hypoglycaemic 
risk, self monitoring of blood glucose (SMBG), and BMI evolution, linked to the cur-
rent treatment. results: A total of 6680 T2DM patients (56% men) were included 
in the 2012 study cohort. The mean age was 66.6 years (25% of patients above 75 
years); 19% had moderate to severe renal impairment and 56% had cardiovascular 
history. The new HAS guidelines split patients into several categories with associ-
ated HbA1c objectives varying from 6.5% to 9% based on age, frailty, diabetes history, 
and co-morbidities. 4%, 35%, 43%, and 18% of diabetic patients were eligible for the 
6.5%, 7%, 8%, and 9% HbA1c objectives respectively. It appears that 55% of the dia-
betic population were at risk of hypoglycaemia, age and long diabetes history being 
the major risk factors. Given the modulation of glycaemic objectives more patients 
reached the new HbA1c objectives (74% of patients) vs. previous guidelines (about 
55%). In this representative cohort, SU were prescribed with no dosage adjustment 
to all patients and even more frequently to patients at risk of hypoglycaemia (60.6%) 
while DDP4i were prescribed to “healthy patients” mostly not at risk of hypoglycae-
mia (51.5%). ConClusions: A minority of T2DM patients (39%) are eligible for an 
HbA1c objective of 7% or below, highlighting their frailty. This survey also shows that 
more patients are reaching their HbA1c target. However many of them are receiving 
treatments they should not due to high risk of hypoglycaemia.
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objeCtives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. This study examines 
these impacts in Germany and compares findings to data from US, UK, Canada 
and China. Methods: A 5 country web-based survey was conducted. MPs were 
defined as: unintentionally forgetting to take insulin (UF), questioning if insulin 
had been taken (QT), or questioning amount of dose (QD). results: A total of 350 
German respondents (60.0% Type 1) completed the survey, 61.1% male, mean age of 
39.5 (±13.3) and mean age of diabetes onset 30.2 (±12.6). The prevalence of MPs in the 
past month was: 74.0% UF, 82.0% QT and 68.3% QD. MPs occurred most frequently 
when waking in the morning or when relaxing. Between 27.9% (UF) – 48.3% (QD) of 
respondents skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP. Patients experiencing MPs required between 2.0 (QT)–8.7 (UF) 
hours, on average, to return to normal blood glucose range, conducted between 1.2 
(QT) –4.4 (UF) extra BG monitoring tests, reported a moderate negative impact on 
their physical and emotional functioning, work absenteeism or reduced ability to 
function optimally when at work and between 3.6% (QT) and 13.8% (QD) visited/
contacted their health care provider due to MPs. Compared to the total sample 
(N= 1404), German respondents were more likely to report that their diabetes was 
very well/well controlled and that they were very/extremely confident in knowing 
what to do when they had an MP compared to respondents and were less likely 
than patients in other countries to have contact with a physician or other health 
care professional following a MP. ConClusions: These findings suggest that MPs 
and 14/12% (N/D) contacted a health care professional. In the week after an event, 
respondents added an average of 2.8/3.6 (N/D) blood glucose tests to an average of 
18.8/17.4 (N/D) tests in a normal week. Nocturnal events had a high impact on sleep 
quality (46% of respondents) and social life (24%), and 84% of respondents felt tired 
and/or fatigued the next day. In the daytime survey, about 26% reported the event 
highly impacted daily activities (outside of work). Also, 40/18% (N/D) of respondents 
indicated that the event had a high impact on their fear of hypoglycaemia. The 
majority ascribed hypoglycaemia to stress (50%/58% [N/D]) or irregular/insufficient 
food intake (50%/40% [N/D]). ConClusions: Both nocturnal and daytime hypogly-
caemic events had an impact on patients’ use of health care system, quality of life 
and daily productivity.
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objeCtives: To investigate the clinical significance of change in QoL-AGHDA 
score after 1 year of growth hormone (GH) replacement. Methods: Observational 
data were obtained from KIMS (Pfizer International Metabolic Database). Minimal 
important differences (MID) for the QoL-AGHDA score and its five domains (mem-
ory and concentration, tenseness, tiredness, self-confidence, and social isolation) 
were calculated using an anchor-based approach with a rating of patient-perceived 
treatment benefit and patient-reported change in need for assistance. Perception 
of treatment benefit was measured using the KIMS Patient Life Situation Form 
(PLSF), a 5-point ordinal assessment of change (much improved, a little improved, 
no change, a little worse, much worse). The effect of baseline (BL) scores on MID 
was analysed using the QoL-AGHDA thresholds included in the New Zealand (≥ 16) 
and England (≥ 11) reimbursement criteria. results: Data from 1404 patients 
(52% female, 96% Caucasian, mean age [SD] of 45 [14] years) were included in the 
analysis. Mean GH dose [SD]was 0.20 [0.14] mg/day at BL and 0.32 [0.16] mg/day 
during Year 1. The Spearman correlation between change in QoL-AGHDA score 
and perception of treatment benefit was moderately positive (0.45; p < 0.01). The 
correlation was stronger for females and for patients with more impaired (higher) 
BL QoL-AGHDA scores. Using the anchor-based approach with patient-perceived 
treatment benefit, the MID for the QoL-AGHDA score was -4.61 at Year 1. Self-
confidence was most sensitive and tenseness least sensitive of the domains in 
predicting patient-perceived treatment benefit. Patients requiring assistance at 
BL and not at Year 1 experienced the largest mean improvement in QoL-AGHDA 
score. ConClusions: Several national reimbursement authorities currently 
include the QoL-AGHDA score in eligibility criteria for access to reimbursed GH 
replacement. This is the first study to calculate the MID for the QoL-AGHDA score. 
Findings indicate that change in QoL-AGHDA score is positively correlated with 
patient-perceived treatment benefit.
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objeCtives: This study examined the effects of nocturnal and daytime non-severe 
hypoglycaemic events on utilisation of health care services and patient quality of 
life in Brazil. Methods: People with diabetes from six different countries who 
had experienced a non-severe hypoglycaemic event in the past 4 weeks were 
asked to take part in a nocturnal and/or daytime hypoglycaemia survey. In the 
Brazilian subgroup, 86 people responded (50 respondents per survey). The sur-
veys were conducted either face to face or online; hypoglycaemic events were 
self-reported. results: In the Brazilian cohort (nocturnal [N]/daytime [D] survey, 
respectively), 80% (N)/76% (D) had type 2 diabetes, 46%/38% (N/D) were male, mean 
age was 41(N)/40(D) years and mean weight was 82.4 kg(N)/81.8 kg (D). Participants 
received treatment with insulin (53%/70% [N/D]), oral medication (61%/60% [N/D]), 
GLP-1 (0%/8% [N/D]) and/or diet and exercise (32%/45% [N/D]). Approximately a 
quarter of respondents (26%/22% [N/D]) reported that they generally experienced 
a hypoglycaemic episode at least once a week. After the non-severe nocturnal (N)/
daytime (D) hypoglycaemic event, 29% and 53% (N/D) decreased their insulin dose 
and 38% and 50%, respectively, contacted a health care professional. Participants 
used on average 13.0 or 11.5 (N/D) extra blood glucose tests the following week and 
56%/32% (N/D) of the surveyed reported a high level of fear of a hypoglycaemic event. 
Among the 44/43 (N/D) respondents who worked for pay, 48%/35% (N/D) went to 
work late or left early; 23%/9% (N/D) missed ≥ 1 full days due to the non-severe event 
and 55%/26% (N/D) said that the event highly impacted upon their productivity at 
work. ConClusions: In Brazil, nocturnal and daytime non-severe hypoglycaemic 
events severely impact upon patients’ quality of life and work productivity, with half 
of patients surveyed decreasing their insulin dose and/or contacting their health 
care provider after a non-severe event.
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